Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
B 12.26 0.70% 0.09
FOLD closed up 6.85 percent on Friday, June 2, 2023, on 1.25 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.70%
Crossed Above 200 DMA Bullish 0.70%
Crossed Above 50 DMA Bullish 0.70%
MACD Bullish Signal Line Cross Bullish 0.70%
Expansion Pivot Buy Setup Bullish Swing Setup 0.70%
Pocket Pivot Bullish Swing Setup 0.70%
Up 3 Days in a Row Strength 0.70%
Up 4 Days in a Row Strength 0.70%
50 DMA Resistance Bearish 7.59%
Outside Day Range Expansion 7.59%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 3 hours ago
Expansion Pivot Buy Entry about 4 hours ago
Rose Above Previous Day's High about 4 hours ago
Down 1% about 4 hours ago
Up 5% 3 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Amicus Therapeutics, Inc. Description

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Orphan Drug Inborn Errors Of Metabolism Lipid Storage Disorders Orphan Disease Enzyme Replacement Therapy Fabry Disease Lysosomal Storage Disorder Gaucher Disease Lysosomal Storage Disorders Pompe Disease Rare And Orphan Diseases

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.84
52 Week Low 7.78
Average Volume 1,886,247
200-Day Moving Average 11.63
50-Day Moving Average 11.46
20-Day Moving Average 11.55
10-Day Moving Average 11.54
Average True Range 0.47
RSI (14) 59.84
ADX 15.73
+DI 26.35
-DI 19.77
Chandelier Exit (Long, 3 ATRs) 11.07
Chandelier Exit (Short, 3 ATRs) 11.97
Upper Bollinger Bands 12.39
Lower Bollinger Band 10.72
Percent B (%b) 0.87
BandWidth 14.42
MACD Line -0.01
MACD Signal Line -0.04
MACD Histogram 0.0296
Fundamentals Value
Market Cap 3.17 Billion
Num Shares 261 Million
EPS -2.13
Price-to-Earnings (P/E) Ratio -5.71
Price-to-Sales 24.35
Price-to-Book 18.91
PEG Ratio -0.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.36
Resistance 3 (R3) 13.24 12.72 13.16
Resistance 2 (R2) 12.72 12.41 12.78 13.10
Resistance 1 (R1) 12.44 12.23 12.58 12.57 13.03
Pivot Point 11.92 11.92 11.99 11.98 11.92
Support 1 (S1) 11.65 11.62 11.79 11.77 11.31
Support 2 (S2) 11.13 11.43 11.19 11.24
Support 3 (S3) 10.85 11.13 11.18
Support 4 (S4) 10.98